• Home
  • » 
  • Reports
  • » 
  • Antibody Discovery: Services and Platfor...

Antibody Discovery

Antibody Discovery: Services and Platforms, 2017-2027

  • Lowest Price Guaranteed From USD 2,499

  • Published
    June 2017

  • Pages
    306

  • View Count
    6019

  • Buy Now

Example Insights

An updated edition is available at the following link 

View 2nd edition

  1. During the course of our study, we identified more than 60 companies that offer antibody discovery services. Majority (more than 80%) of these antibody discovery service providers are located in North America and EU. Examples of the players based in these regions include (in alphabetical order) Adimab, Aragen Bioscience, Antibody Solutions, Evotec, GenScript, Integral Molecular, ModiQuest Research and PX'Therapeutics.
  2. It is worth highlighting that a number of start-ups have entered this domain to provide contract research services; examples include (in alphabetical order) Ab Studio, Abveris Antibody, AffinityImmuno, ChemBio Discovery Solutions, G&P Biosciences, HiFiBiO, OriMAbs, Panoply Bio and Specifica.
  3. CROs offer antibody discovery services by deploying a variety of methods such as library based (phage display, yeast display and mammalian display), hybridoma, transgenic animal based and single cell based methods. During our research, we observed that a vast majority of companies (31) offer antibody discovery services by using library based methods. This is followed by companies that use hybridoma method (27), single cell based methods (13) and transgenic animal based methods (11). 
  4. Companies that have developed novel antibody drug discovery platforms are providing access / non-exclusive licenses of their proprietary platforms to drug developers, CROs and academic institutes. During the course of our study, we identified more than 20 such platform providers. Around 40% of the antibody discovery platform providers are headquartered in North America, 36% of companies are based in Europe while the remaining (24%) are located in the Asia Pacific region.
  5. Majority (13) of the platforms available for licensing are library based; examples include Abtracer™, ADAPT™, ADLib® library, mAbLogix™ and n-CoDeR® antibody library. There are seven transgenic animal based platforms that are available for licensing; these include AlivaMab™ Mouse, Kymouse™ platform, OmniAb® platforms and TRIANNI Mouse platform.
  6. A number of stakeholders in the field of antibody discovery have entered into collaborations with CROs and / or technology providers. We came across 172 deals that have been signed during the period 2011-2017. Majority (~50%) of the partnerships in this domain are research collaborations; this highlights the fact that extensive research is being conducted to discover novel therapeutic antibodies. Technology licensing is the second most popular partnership model in this field, capturing 32% share. Prominent contract service providers that have entered into multiple partnerships include Adimab, Crystal Biosciences, MAB Discovery, AbCellera and Abzena.
  7. Driven by the rising demand for targeted therapies and innovation in antibody discovery methods, we expect the antibody discovery services market to witness continuous growth in the coming decade. In terms of geography, majority (more than 70%) of the share is distributed between North America and Europe; we believe that China is likely to grow at faster rate (annualized rate of 8.9%) as compared to other regions in the coming decade. With respect to antibody discovery methods, we believe that transgenic animal based method is likely to grow at a faster rate (annualized rate of 6.6%) as compared to the established methods such as phage display and hybridoma methods.  

Report Description

The rising demand of personalized medicines to provide targeted treatment options has encouraged pharmaceutical companies to shift their focus from small molecules to discovery and development of biologics, particularly antibody based therapeutics. Antibodies, because of several advantages such as high specificity and targeted approach, are increasingly becoming crucial for the treatment of a number of diseases. In fact, since 2015, more than 20 antibodies have been approved by the USFDA. The growing popularity of antibody based therapeutics is also reflected from the dominance of these biologics in the portfolios of major biopharmaceutical companies.

At present, the focus of majority of biopharmaceutical companies is on discovering therapeutic antibodies against novel targets. However, discovery of antibodies is a long, arduous and costly process; as a result, there is a growing preference to outsource such operations. Drug developers are partnering with contract research organizations (CROs) that provide antibody discovery services using novel and advanced technologies. Outsourcing enables biopharmaceutical companies / academic institutes accelerate their drug discovery process by leveraging the technical capabilities and expertise of CROs. Additionally, a number of drug developers and academic institutes have obtained rights to access novel antibody discovery platforms from technology providers. As the demand of novel therapeutic antibodies for various disease areas is expected to rise steadily, we are optimistic about the future of the contract research firms that are driving innovation in the drug discovery process.

 

Scope of the Report

The ‘Antibody Discovery: Services and Platforms, 2017-2027’ report provides an extensive study on the current market landscape and future outlook of the antibody discovery service and platform providers. The study presents an in-depth analysis of a diverse set of companies that provide antibody discovery services and / or provide access to their platforms to drug developers. In addition to other elements, the report provides information on the following:

  • The competitive market landscape and industry analysis with respect to key players along with information on their geographical location, type of business operation, methods used for antibody generation and the purpose of antibody discovery (therapeutic and / or diagnostic).
  • Elaborate profiles of established / emerging players that offer a wide range of services in the overall antibody discovery process; each profile includes a brief overview of the company, information on its financial and funding details (if available), antibody discovery service portfolio and novel antibody discovery technology / platforms,and a view on its future outlook and strategy.
  • Most active regions in terms of antibody discovery services and platforms; the report contains schematic representations of world maps that clearly indicate the location of antibody discovery service hubs.
  • Platform competitiveness and supplier power (in the form of 2 X 2 matrices) across the growing landscape of antibody discovery platforms that are available for licensing.
  • A case study covering detailed information on the historical background of drug discovery process of some of the blockbuster therapeutic monoclonal antibodies such as Humira®, Remicade®, Herceptin®, Lucentis®and Simponi®.
  • Partnerships that have taken place in the recent past covering research collaborations, service agreements, license agreements, mergers / acquisitions and other deals signed between industry / non-industry stakeholders.

The study features a detailed analysis of the existing size and potential future growth opportunities (2017-2027) in the antibody discovery services market. We have provided insights on the likely evolution of the market in different regions including North America, Europe, China and rest of the world. In addition, we have provided the likely evolution on the basis of the steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery methods (phage display, hybridoma, transgenic animal based, yeast display, single cell based and others), and the nature of antibody generated (chimeric, humanized and fully human). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have presented three different forecast scenarios, depicting conservative, base and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of the study, we invited over 60 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. These include contributions from Aaron Sato (Chief Scientific Officer, LakePharma), Debra Valsamis (Business Development Associate, Antibody Solutions), Christel Iffland (Vice President, Ligand Pharmaceuticals), Ignacio Pino (President and CEO, CDI Laboratories), Jeng Her (CEO, AP Biosciences) and Thomas Schirrmann (CEO and General Manager, YUMAB).

Contents

Chapter 2  provides an executive summary of the insights captured in our research. The summary offers a high level view on the current state of the antibody discovery services and platforms market and its likely evolution in the mid-long term.

Chapter 3  provides a general overview of antibodies with information on their historical background, structure, isotypes, mechanism of action and applications. It also provides details on the different types of antibodies, such as polyclonal, monoclonal and bispecific antibodies.

Chapter 4  features information on the antibody discovery process and the various antibody discovery methods. It also includes a comparison of the different antibody discovery methods that are available currently. Additionally, the chapter provides insights on the gradual shift in development trends for monoclonal antibodies over the last three decades, from fully murine to fully human variants.

Chapter 5  includes a comprehensive landscape of the companies that offer antibody discovery services and / or provide licenses to their antibody discovery platforms. For the antibody discovery service providers, the chapter includes analyses on the basis of their geographical location, type of business operations, methods used for antibody generation, steps involved in antibody discovery and purpose of antibody discovery (therapeutic and / or diagnostic). For antibody discovery platform providers, the chapter provides analysis based on geographical location and antibody generation methods on which the platforms are based. Additionally, it contains a list of companies that have developed proprietary antibody discovery platforms / technologies to cater to their in-house discovery needs.

Chapter 6  provides detailed profiles of some of the players, based in different geographies, which are actively providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, its financial and funding information ( if available ), details on antibody discovery services and novel antibody discovery technology / platforms, and a view on its future outlook and strategy.

Chapter 7  provides detailed profiles of some of the important players, based in different geographies, which are actively providing access / licenses to their antibody discovery technology / platform to biopharmaceutical companies. Each company profile includes a brief overview of the company, funding instances, financial information ( if available ), details on antibody discovery technology / platforms and a view on its future outlook and strategy. The chapter also presents 2 X 2 matrices, comparing competitiveness and supplier power of the antibody discovery platforms.

Chapter 8  presents a comprehensive view on how the antibody discovery services market is likely to grow over the next ten years. We have segregated the financial opportunity on the basis of different regions (North America, Europe, China and rest of the world), the steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery methods (phage display, hybridoma, transgenic animal based, yeast display, single cell based and others), and the nature of antibody generated (murine, chimeric, humanized and fully human). All our predictions are backed by robust analysis of data procured from both secondary and primary sources. The chapter also presents insightful 2 X 2 matrices to highlight the market share and market attractiveness derived from the current and likely future state of the market. Due to uncertainties surrounding some of the assumptions within our forecast model, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios.

Chapter 9  features an elaborate discussion and analysis on the collaborations and partnerships that have been inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this segment of the overall market.

Chapter 10  provides detailed information on the historical background of drug discovery process of some of the blockbuster therapeutic monoclonal antibodies. The antibodies for which details on discovery process and method are provided include Humira®, Remicade®, Herceptin®, Lucentis® and Simponi®.

Chapter 11  presents insights from the survey conducted for this study. We invited over 60 stakeholders involved in providing antibody discovery services and platforms. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 12  summarizes the overall report. It presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this market in the short and long term.

Chapter 13  is a collection of interview transcripts of our discussions with some of the key players in this industry. We have presented the details of our conversations with Aaron Sato (Chief Scientific Officer, LakePharma), Debra Valsamis (Business Development Associate, Antibody Solutions), Christel Iffland (Vice President, Ligand Pharmaceuticals), Ignacio Pino (President and CEO, CDI Laboratories), Jeng Her (CEO, AP Biosciences) and Thomas Schirrmann (CEO and General Manager, YUMAB).

Chapter 14  is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 15  is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION TO ANTIBODIES
3.1. Chapter Overview
3.2. Historical Background of Antibodies
3.3. Structure of Antibodies
3.4. Isotypes of Antibodies
3.5. Mechanism of Action of Antibodies
3.6. Polyclonal and Monoclonal Antibodies
3.7. Bispecific Antibodies
3.8. Applications of Antibodies
 
4. ANTIBODY DISCOVERY PROCESS AND METHODS
4.1. Chapter Overview
4.2. Antibody Discovery Process
4.2.1. Target Selection and Validation
4.2.2. Hit Generation
4.2.3. Lead Selection
4.2.4. Lead Optimization
4.2.4.1. Humanization
4.2.4.2. Affinity Maturation
4.2.4.3. Fc Engineering
4.2.5. Lead Characterization
4.2.6. Candidate Selection
 
4.3. Antibody Discovery Methods
4.3.1. Hybridoma Method
4.3.2. In Vitro Display Methods
4.3.2.1. Phage Display Method
4.3.2.2. Yeast Display Method
4.3.2.3. Ribosomal Display Method
4.3.3. Transgenic Animals Based Method
4.3.4. Single B cell Based Method
4.4. Advantages and Disadvantages of Antibody Discovery Methods
4.5. Evolution of Monoclonal Antibodies: From Murine to Fully Human
 
5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Antibody Discovery Services Providers: Overall Market Landscape
5.2.1. Antibody Discovery Services Providers: Analysis by Business Operation
5.2.2. Antibody Discovery Services Providers: Analysis by Steps Involved in Antibody Discovery
5.2.3. Antibody Discovery Services Providers: Analysis by Antibody Generation Methods
5.2.4. Antibody Discovery Services Providers: Analysis by Purpose of Antibody Discovery
 
5.3. Antibody Discovery Platform Providers: Overall Market Landscape
5.3.1. Antibody Discovery Platform Providers: Analysis by Antibody Generation Methods
5.4. Antibody Discovery Platforms Used for In-house Purposes
 
6. ANTIBODY DISCOVERY SERVICES PROVIDERS
6.1. Overview
6.2. Antibody Discovery Services Providers: North America
6.2.1. Abwiz Bio
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Antibody Discovery Services
6.2.1.4. Antibody Discovery Platforms
6.2.1.4.1. Needle-in-a-Haystack Technology™
6.2.1.4.2. RabWiz™
6.2.1.4.3. WizAmp™
6.2.1.5. Recent Developments
6.2.1.5.1. Partnerships
6.2.1.6. Future Outlook
 
6.2.2. Aragen Bioscience (A GVK BIO Company)
6.2.2.1. Company Overview
6.2.2.2. Antibody Discovery Services
6.2.2.3. Recent Developments
6.2.2.3.1. Expansions
6.2.2.3.2. Partnerships
6.2.2.4. Future Outlook
 
6.2.3. LakePharma
6.2.3.1. Company Overview
6.2.3.2. Antibody Discovery Services
6.2.3.3. Recent Developments
6.2.3.3.1. Expansions
6.2.3.3.2. Partnerships
6.2.3.4. Future Outlook
 
6.3. Antibody Discovery Service Providers: Europe
6.3.1. Abzena
6.3.1.1. Company Overview
6.3.1.2. Financial Information
6.3.1.3. Antibody Discovery Services
6.3.1.4. Recent Developments
6.3.1.4.1. Expansions
6.3.1.4.2. Partnerships
6.3.1.5. Future Outlook
 
6.3.2. ModiQuest Research (Subsidiary of ModiQuest Group)
6.3.2.1. Company Overview
6.3.2.2. Antibody Discovery Services
6.3.2.3. Antibody Discovery Platforms
6.3.2.3.1. ModiVacc™: Proprietary Hyper-Immune Stimulatory Cell Immunization Platform
6.3.2.3.2. ModiFuse™: Proprietary Hybridoma Platform
6.3.2.3.3. ModiSelect™: Proprietary B Cell Selection Platform
6.3.2.3.4. ModiPhage™: In-House and Custom Phage Libraries
6.3.2.3.5. ModiTune™: Antibody Optimization Platform
6.3.2.3.6. ModiXpress™: Proprietary In-House Expression Platform
6.3.2.4. Recent Developments
6.3.2.4.1. Partnerships
6.3.2.5. Future Outlook
 
6.3.3. PX'Therapeutics (a Subsidiary of Aguettant Pharmaceutical Group)
6.3.3.1. Company Overview
6.3.3.2. Antibody Discovery Services
6.3.3.3. Recent Developments
6.3.3.3.1. Partnerships
6.3.3.4. Future Outlook
 
6.4. Antibody Discovery Service Providers: Asia Pacific
6.4.1. ChemPartner
6.4.1.1. Company Overview
6.4.1.2. Antibody Discovery Services
6.4.1.3. Recent Developments
6.4.1.3.1. Expansions
6.4.1.3.2. Partnerships
6.4.1.4. Future Outlook
 
6.4.2. Viva Biotech
6.4.2.1. Company Overview
6.4.2.2. Antibody Discovery Services
6.4.2.3. Recent Developments
6.4.2.3.1. Partnerships
6.4.2.4. Future Outlook
 
6.4.3. WuXi AppTec
6.4.3.1. Company Overview
6.4.3.2. Financial Information
6.4.3.3. Antibody Discovery Services
6.4.3.4. Recent Developments
6.4.3.4.1. Expansions
6.4.3.4.2. Partnerships
6.4.3.5. Future Outlook
 
7. ANTIBODY DISCOVERY PLATFORM PROVIDERS
7.1. Chapter Overview
7.2. Antibody Discovery Platform Providers: North America
7.2.1. Ligand Pharmaceuticals
7.2.1.1. Company Overview
7.2.1.2. Financial Information
7.2.1.3. Antibody Discovery Platforms
7.2.1.3.1. OmniAb
7.2.1.3.1.1. OmniRat
7.2.1.3.1.2. OmniMouse
7.2.1.3.1.3. OmniFlic
7.2.1.4. Patent Portfolio
7.2.1.5. Recent Developments
7.2.1.6. Future Outlook
 
7.2.2. TRIANNI
7.2.2.1. Company Overview
7.2.2.2. The TRIANNI Mouse™ Platform
7.2.2.3. Patent Portfolio
7.2.2.4. Recent Developments
7.2.2.5. Future Outlook
 
7.3. Antibody Discovery Platform Providers: Europe
7.3.1. AIMM Therapeutics
7.3.1.1. Company Overview
7.3.1.2. Financial Information
7.3.1.3. AIMSelect™
7.3.1.4. Recent Developments
7.3.1.5. Future Outlook
 
7.3.2. Kymab
7.3.2.1. Company Overview
7.3.2.2. Financial Information
7.3.2.3. Kymouse™
7.3.2.4. Patent Information
7.3.2.5. Recent Developments
7.3.2.6. Future Outlook
 
7.4. Antibody Discovery Platform Providers: Asia Pacific
7.4.1. Harbour BioMed
7.4.1.1. Company Overview
7.4.1.2. Financial Information
7.4.1.3. Antibody Discovery Platforms
7.4.1.3.1. H2L2
7.4.1.3.2. HCAb
7.4.1.4. Patent Information
7.4.1.5. Recent Developments
7.4.1.6. Future Outlook
 
7.5. Competitiveness Analysis: Antibody Discovery Platforms
7.5.1. Competitiveness Analysis: Library Based Antibody Discovery Platforms
7.5.2. Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms
 
8. OPPORTUNITY ANALYSIS
8.1. Chapter Overview
8.2. Forecast Methodology
8.3. Antibody Discovery Services Market, 2017-2027 (USD Billion)
8.4. Antibody Discovery Services Market, 2017-2027: Distribution by Regions (USD Billion)
8.4.1. Antibody Discovery Services Market: North America, 2017-2027 (USD Billion)
8.4.2. Antibody Discovery Services Market: Europe, 2017-2027 (USD Billion)
8.4.3. Antibody Discovery Services Market: China, 2017-2027 (USD Billion)
8.4.4. Antibody Discovery Services Market: Rest of the World, 2017-2027 (USD Billion)
8.4.5. Antibody Discovery Services: Market Attractiveness Analysis by Region
8.5. Antibody Discovery Services Market, 2017-2027: Distribution by Steps Involved in Antibody Discovery Process (USD Billion)
8.6. Antibody Discovery Services Market, 2017-2027: Distribution by Antibody Discovery Methods (USD Billion)
8.6.1. Antibody Discovery Services: Market Attractiveness Analysis by Antibody Discovery Method
8.7. Antibody Discovery Services Market, 2017-2027: Distribution by Nature of Antibody Generated (USD Billion)
 
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Antibody Discovery Services and Platforms: List of Partnerships
9.3.1. Antibody Discovery Services and Platforms: Distribution of Partnerships by Year
9.3.2. Antibody Discovery Services and Platforms: Distribution of Partnerships by Type
9.3.3. Antibody Discovery Services and Platforms: Leading Players by Number of Partnerships
 
10. CASE IN POINT: DRUG DISCOVERY PROCESS OF TOP SELLING ANTIBODIES
10.1. Chapter Overview
10.2. Humira  (Adalimumab)
10.2.1. Drug Overview
10.2.2. Discovery Process and Method
 
10.3. Remicade (Infliximab)
10.3.1. Drug Overview
10.3.2. Discovery Process and Method
 
10.4. Herceptin (Trastuzumab)
10.4.1. Drug Overview
10.4.2. Discovery Process and Method
10.5. Lucentis (Ranibizumab)
10.5.1. Drug Overview
10.5.2. Discovery Process and Method
 
10.6. Simponi (Golimumab)
10.6.1. Drug Overview
10.6.2. Discovery Process and Method
 
11. SURVEY ANALYSIS
11.1. Chapter Overview
11.2. Seniority Level of Respondents
11.3. Steps of Antibody Discovery for which Services are Provided
11.4. Antibody Discovery Methods
11.5. Type of Antibody Discovered
11.6. Location of Antibody Discovery Facility / Laboratory
11.7. Likely Market Size
 
12. CONCLUSION
12.1. High Costs, Process Complexity and Lack of Internal Resources have Led to Increased Outsourcing in Antibody Discovery
12.2. A Number of Platform Providers, With an Aim to Support Antibody Discovery Operations of Drug Developers / CROs, have Emerged
12.3. Flexible Partnership Models have Fostered Collaborations between Drug Developers and CROs / Technology Providers
12.4. In Order to Maintain a Competitive Edge in the Growing Antibody Discovery Field, the Companies are Developing Innovative Technologies
12.5. Driven by the Rising Demand for Targeted Therapies, the Market is Likely to Witness Continuous Growth in the Coming Decade
 
13. INTERVIEW TRANSCRIPTS
13.1. Chapter Overview
13.2. Aaron Sato, Chief Scientific Officer, LakePharma
13.3. Debra Valsamis, Business Development Associate, Antibody Solutions
13.4. Christel Iffland, Vice President, Ligand Pharmaceuticals
13.5. Ignacio Pino, President and CEO, CDI Laboratories
13.6. Jeng Her, CEO, AP Biosciences
13.7. Thomas Schirrmann, CEO and General Manager, YUMAB
 
14. APPENDIX 1: TABULATED DATA
 
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 2.1  Antibody Discovery Services: Market Attractiveness Analysis by Region
Figure 2.2  Antibody Discovery Services: Market Attractiveness Analysis by Antibody Discovery Method
Figure 3.1  Historical Timeline of Antibody Development
Figure 3.2  Basic Structure of Antibody
Figure 3.3  Mechanism of Action of Antibodies
Figure 3.4  Monoclonal Antibodies: Nomenclature
Figure 3.5  Applications of Antibodies
Figure 4.1  An Overview of the Antibody Discovery Process
Figure 4.2  Hybridoma Method
Figure 4.3  Phage Display Method
Figure 4.4  Antibody Generation Using Transgenic Animals
Figure 4.5  Approved Monoclonal Antibodies: Development Trend Analysis
Figure 4.6  Approval Timeline: Fully Human Monoclonal Antibody
Figure 4.7  Fully Human Monoclonal Antibodies: Distribution by Discovery Method
Figure 5.1  Antibody Discovery Services Providers: Distribution by Geography
Figure 5.2  Antibody Discovery Services Providers: Distribution by Business Operation
Figure 5.3  Antibody Discovery Services Providers: Distribution by Steps Involved in Antibody Discovery
Figure 5.4  Antibody Discovery Services Providers: Antibody Generation Methods
Figure 5.5  Antibody Discovery Services Providers: Distribution by Purpose of Antibody Discovery
Figure 5.6  Antibody Discovery Platform Providers: Distribution by Geography
Figure 5.7  Antibody Discovery Platform Providers: Distribution by Antibody Generation Methods
Figure 6.1  Aragen Bioscience: Service Portfolio
Figure 6.2  Aragen Bioscience: Antibody Discovery Services
Figure 6.3  LakePharma: Service Portfolio
Figure 6.4  LakePharma: Antibody Discovery Services
Figure 6.5  Abzena: Service Portfolio
Figure 6.6  Abzena: Annual Revenues, 2013-2016 (EUR Million)
Figure 6.7  ModiQuest Research: Service Portfolio
Figure 6.8  ModiQuest Research: Antibody Discovery Services and Platforms
Figure 6.9  PX’Therapeutics: Service Portfolio
Figure 6.10  ChemPartner: Service Portfolio
Figure 6.11  Viva Biotech: Service Portfolio
Figure 6.12  Viva Biotech: Antibody Discovery Services
Figure 6.13 WuXi Biologics: Service Portfolio
Figure 6.14  WuXi AppTec: Annual Revenues, 2012-Q3 2015 (USD Million),
Figure 6.15  WuXi Biologics: Antibody Discovery Services
Figure 7.1  Ligand Pharmaceuticals: Technology Portfolio
Figure 7.2  Ligand Pharmaceuticals: Annual Revenues, 2012-Q1 2017  (USD Million)
Figure 7.3  AIMM Therapeutics: Technology Platforms
Figure 7.4  Competitiveness Analysis:  Library Based Antibody Discovery Platforms
Figure 7.5  Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms
Figure 8.1  Antibody Discovery Services Market, 2017-2027: Base Scenario (USD Billion)
Figure 8.2  Antibody Discovery Services Market, 2017 and 2027:  Distribution by Regions (%)
Figure 8.3  Antibody Discovery Services Market, 2017-2027: North America, Base Scenario (USD Billion)
Figure 8.4  Antibody Discovery Services Market, 2017-2027: Europe, Base Scenario (USD Billion)
Figure 8.5  Antibody Discovery Services Market, 2017-2027: China, Base Scenario (USD Billion)
Figure 8.6  Antibody Discovery Services Market, 2017-2027: Rest of the World, Base Scenario (USD Billion)
Figure 8.7 Antibody Discovery Services: Market Attractiveness Analysis by Region
Figure 8.8  Antibody Discovery Services Market, 2017-2027: Distribution by Steps Involved in Antibody Discovery Process, Base Scenario (USD Billion)
Figure 8.9  Antibody Discovery Services Market, 2017, 2022, 2027: Distribution by Antibody Discovery Methods (%)
Figure 8.10  Antibody Discovery Services Market, 2017-2027: Distribution by Antibody Discovery Methods, Base Scenario (USD Billion)
Figure 8.11  Antibody Discovery Services: Market Attractiveness Analysis by Antibody Discovery Method
Figure 8.12  Antibody Discovery Services Market, 2017 and 2027: Distribution by Nature of Antibody Generated, Base Scenario (%)
Figure 8.13  Antibody Discovery Services Market, 2017-2027: Distribution by Nature of Antibody Generated, Base Scenario (USD Billion)
Figure 9.1  Antibody Discovery Services and Platforms: Number of Partnerships by Year (2011-2017)
Figure 9.2  Antibody Discovery Services and Platforms Providers: Distribution by Type of Partnership
Figure 9.3  Antibody Discovery Services and Platforms: Leading Players by Number of Partnerships
Figure 11.1  Survey Analysis: Distribution by Geography
Figure 11.2  Survey Analysis: Seniority Levels of Respondents
Figure 11.3  Survey Analysis: Distribution by Steps of Antibody Discovery Services
Figure 11.4  Survey Analysis: Distribution by Antibody Discovery Methods
Figure 11.5  Survey Analysis: Distribution by Type Antibody Discovered
Figure 11.6 Survey Analysis: Location of Antibody Discovery Facility / Laboratory
Figure 11.7  Survey Analysis: Likely Current Market Size
Figure 12.1  Antibody Discovery Services Market: 2017, 2022 and 2027 (USD Billion)

List of Tables

Table 3.1  Features of Different Isotypes of Antibodies
Table 3.2  Mechanism of Action of Therapeutic Antibodies Against Different Target Classes
Table 3.3  Difference Between Polyclonal and Monoclonal Antibodies
Table 4.1  Antibody Discovery Methods: Advantages and Disadvantages
Table 4.2  List of Approved Monoclonal Antibodies
Table 5.1  Antibody Discovery: List of Services Providers
Table 5.2  Antibody Discovery Services Providers: Distribution by Type of Business Operation
Table 5.3  Antibody Discovery Service Providers: Distribution by Steps of Antibody Discovery
Table 5.4  Antibody Discovery Services Providers: Distribution by Antibody Generation Method
Table 5.5  Antibody Discovery Services Providers: Distribution by Purpose of Antibody  Discovery
Table 5.6 List of Antibody Discovery Platform Providers 
Table 5.7  Antibody Discovery Platform Providers: Distribution by Antibody Generation Method
Table 5.8  Antibody Discovery Platforms Used for In-house Purposes
Table 6.1  Antibody Discovery Services: List of Companies Profiled
Table 6.2  WuXi AppTec: Funding Instances
Table 7.1  Antibody Discovery Platforms: List of Companies Profiled
Table 7.2  OmniAb® Technology: Key Features
Table 7.3  OmniAb® Technology: Patent Information
Table 7.4  TRIANNI Mouse™: Key Features
Table 7.5  AIMSelect™ Platform: Key Features
Table 7.6 Kymab: Funding Instances
Table 7.7  Kymouse: Key Features
Table 7.8  H2L2 Platform: Key Features
Table 7.9  HCAb Platform: Key Features
Table 9.1  Antibody Discovery Services and Platforms: List of Partnerships
Table 10.1  Top Ten Selling Therapeutic Antibodies, 2016
Table 11.1  Survey Response: Overview of the Participating Companies
Table 11.2  Survey Response: Seniority Level of Respondents
Table 11.3  Survey Response: Steps of Antibody Discovery Services
Table 11.4  Survey Response: Antibody Discovery Methods
Table 11.5  Survey Response: Type of Antibody Discovered
Table 11.6  Survey Response: Location of Antibody Discovery Facility / Laboratory
Table 11.7  Survey Response: Likely Current Market Size
Table 14.1  Approved Monoclonal Antibodies: Development Trend Analysis
Table 14.2  Fully Human Monoclonal Antibodies: Distribution by Discovery Method
Table 14.3  Antibody Discovery Services Providers: Distribution by Business Operation
Table 14.4  Antibody Discovery Services Providers: Distribution by Steps Involved in Antibody Discovery
Table 14.5  Antibody Discovery Services Providers: Distribution by Antibody Generation Method
Table 14.6  Antibody Discovery Services Providers: Distribution by Purpose of Antibody Discovery
Table 14.7  Antibody Discovery Platform: Distribution by Antibody Generation Methods
Table 14.8  Abzena: Annual Revenues, 2013-H1 2016 (EUR Million)
Table 14.9  WuXi AppTec: Annual Revenues, 2012-Q3 2015 (USD Million)
Table 14.10  Ligand Pharmaceuticals: Annual Revenues, 2012-Q1 2017 (USD Million)
Table 14.11  Antibody Discovery Services Market, 2017-2027: Conservative Scenario (USD  Billion)
Table 14.12  Antibody Discovery Services Market, 2017-2027: Base Scenario (USD Billion)
Table 14.13  Antibody Discovery Services Market, 2017-2027: Optimistic Scenario (USD Billion)
Table 14.14  Antibody Discovery Services Market, 2017 and 2027:  Distribution by Region (%)
Table 14.15  Antibody Discovery Services Market, 2017-2027: North America, Conservative Scenario (USD Billion)
Table 14.16  Antibody Discovery Services Market, 2017-2027: North America, Base Scenario (USD Billion)
Table 14.17  Antibody Discovery Services Market, 2017-2027: North America, Optimistic Scenario (USD Billion)
Table 14.18  Antibody Discovery Services Market, 2017-2027: Europe, Conservative Scenario (USD Billion)
Table 14.19  Antibody Discovery Services Market, 2017-2027: Europe, Base Scenario (USD Billion)
Table 14.20  Antibody Discovery Services Market, 2017-2027: Europe, Optimistic Scenario (USD Billion)
Table 14.21  Antibody Discovery Services Market, 2017-2027: China, Conservative Scenario (USD Billion)
Table 14.22  Antibody Discovery Services Market, 2017-2027: China, Base Scenario (USD Billion)
Table 14.23  Antibody Discovery Services Market, 2017-2027: China, Optimistic Scenario (USD Billion)
Table 14.24  Antibody Discovery Services Market, 2017-2027: Rest of the World, Conservative Scenario (USD Billion)
Table 14.25  Antibody Discovery Services Market, 2017-2027: Rest of the World, Base Scenario (USD Billion)
Table 14.26  Antibody Discovery Services Market, 2017-2027: Rest of the World, Optimistic Scenario (USD Billion)
Table 14.27  Antibody Discovery Services: Market Attractiveness Analysis by Region
Table 14.28  Antibody Discovery Services Market, 2017-2027: Distribution by Steps Involved in Antibody Discovery Process, Conservative Scenario (USD Billion)
Table 14.29  Antibody Discovery Services Market, 2017-2027: Distribution by Steps Involved in Antibody Discovery Process, Base Scenario (USD Billion)
Table 14.30  Antibody Discovery Services Market, 2017-2027: Distribution by Steps Involved in Antibody Discovery Process, Optimistic Scenario (USD Billion)
Table 14.31  Antibody Discovery Services Market, 2017, 2022, 2027: Distribution by Antibody Discovery Methods (%)
Table 14.32  Antibody Discovery Services Market, 2017-2027: Distribution by Antibody Discovery Methods, Conservative Scenario (USD Billion)
Table 14.33  Antibody Discovery Services Market, 2017-2027: Distribution by Antibody Discovery Methods, Base Scenario (USD Billion)
Table 14.34  Antibody Discovery Services Market, 2017-2027: Distribution by Antibody Discovery Methods, Optimistic Scenario (USD Billion)
Table 14.35  Antibody Discovery Services: Market Attractiveness Analysis by Antibody Discovery Method
Table 14.36  Antibody Discovery Services Market, 2017 and 2027: Distribution by Nature of Antibody Generated (%)
Table 14.37  Antibody Discovery Services Market, 2017-2027: Distribution by Nature of Antibody Generated, Conservative Scenario (USD Billion)
Table 14.38  Antibody Discovery Services Market, 2017-2027: Distribution by Nature of Antibody Generated, Base Scenario (USD Billion)
Table 14.39  Antibody Discovery Services Market, 2017-2027: Distribution by Nature of Antibody Generated, Optimistic Scenario (USD Billion)
Table 14.40  Antibody Discovery Services and Platforms: Number of Partnerships by Year (2011-2017)
Table 14.41  Antibody Discovery Service and Platform Providers: Distribution by Type of Partnership
Table 14.42  Antibody Discovery Services and Platforms: Leading Players by Number of Partnerships
Table 14.43  Survey Analysis: Distribution by Geography
Table 14.44  Survey Analysis: Seniority Levels of Respondents
Table 14.45  Survey Analysis: Distribution by Steps of Antibody Discovery Services
Table 14.46  Survey Analysis: Distribution by Antibody Discovery Methods
Table 14.47  Survey Analysis: Distribution by Type Antibody Discovered
Table 14.48  Survey Analysis: Location of Antibody Discovery Facility / Laboratory
Table 14.49  Survey Analysis: Likely Current Market Size
Table 14.50  Antibody Discovery Services Market: 2017, 2022 and 2027 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report. 

  1. 4-Antibody
  2. ABBA Therapeutics
  3. AbGenics Life Sciences
  4. AbBioSci
  5. AB Biosciences
  6. Abbott Laboratories
  7. AbbVie
  8. AbCellera
  9. AbCheck
  10. Abgent
  11. Abeome 
  12. Ablexis
  13. Abpro
  14. Ab Studio
  15. Abveris Antibody
  16. Abwiz Bio
  17. Abzena
  18. Abzyme Therapeutics
  19. Accurus Biosciences
  20. Acceleron Pharma
  21. Achaogen
  22. ACYTE Biotech
  23. Adimab
  24. Aduro Biotech
  25. Advantech Capital
  26. AffinityImmuno
  27. Affitech
  28. Agenus
  29. Agilent Technologies
  30. Aguettant Pharmaceutical
  31. AIMM Therapeutics
  32. Akeso Biopharma
  33. Alcon
  34. Aldevron
  35. Alder BioPharmaceuticals
  36. Alector
  37. Alere
  38. Alexion Pharmaceuticals
  39. Ambrx
  40. Amgen
  41. Anaimmune
  42. AnaptysBio
  43. Antagene
  44. Antitope
  45. Antibody Solutions
  46. AP Biosciences
  47. Apexigen
  48. Aragen Bioscience
  49. arGEN-X
  50. Aridis Pharmaceuticals
  51. Aristi Biotech
  52. AstraZeneca 
  53. Atreca
  54. Austrianni
  55. AvantGen
  56. AxioMx
  57. BASF Bioresearch Corporation
  58. Baylor Scott & White Research Institute
  59. Bayer Pharma
  60. Bill & Melinda Gates Foundation
  61. BioAtla
  62. Biogen
  63. BioInvent
  64. Biolauncher
  65. BioNTech
  66. BioRap Technologies
  67. BioSavita
  68. BIOTEM
  69. Bird Rock Bio
  70. bluebird bio
  71. Boehringer Ingelheim
  72. Boston Children's Hospital
  73. Brigham and Women’s Hospital
  74. Bristol-Myers Squibb
  75. Cambridge Antibody Technology
  76. Cancer Research Technology
  77. CDI Laboratories
  78. Celgene
  79. Cellectis
  80. Centers for Disease Control and Prevention
  81. Centocor Biotech
  82. Charles River Laboratories
  83. ChemBio Discovery Solutions
  84. ChemPartner
  85. Chiome Bioscience
  86. Chugai Pharmaceutical
  87. Chugai Pharmabody Research
  88. CIS Bio
  89. Commerce Health Capital
  90. Compass Therapeutics
  91. Compugen
  92. ContraFect
  93. CorMatrix
  94. Corixa 
  95. Cosmo Pharmaceuticals
  96. Creative Biolabs
  97. Crelux
  98. Crescendo Biologics
  99. Cresset Biomolecular Discovery
  100. Crucell
  101. Crystal Biosciences
  102. Cytogen
  103. Daiichi Sankyo
  104. Dako
  105. Defense Threat Reduction Agency (DTRA)
  106. DJS Antibodies
  107. Digital Proteomics
  108. Distributed Bio
  109. Dyax
  110. Effimune
  111. Eight Roads Ventures
  112. Elan
  113. Eli Lilly
  114. Elusys Therapeutics
  115. Emergent BioSolutions
  116. Enumeral
  117. Epimab Biotherapeutics
  118. Erasmus University Medical Center
  119. Essex Bio
  120. Eureka Therapeutics
  121. Evotec
  122. Exonbio
  123. Exiris
  124. FairJourney Biologics
  125. Five Prime Therapeutics
  126. Fred Hutchinson Cancer Research Center
  127. French Institute of Health and Medical Research (INSERM)
  128. Fresenius
  129. Fusion Antibodies  
  130. G&P Biosciences
  131. GeneFrontier Corporation
  132. Genentech
  133. Genmab
  134. Genor Biopharma
  135. GenScript
  136. Genzyme
  137. Georgia Institute of Technology
  138. GigaGen
  139. Gilead Sciences
  140. GlaxoSmithKline
  141. Grenoble Hospital
  142. GVK BIO
  143. Harbour Antibodies
  144. Harbour BioMed
  145. HD Biosciences
  146. Henlix Biotech
  147. Hepalink
  148. Heptares Therapeutics
  149. HiFiBiO - High Fidelity Biology
  150. HitGen
  151. HQL Pharmaceuticals
  152. HUMABS BioMed
  153. Human Genome Sciences
  154. Ibex Biosciences
  155. Icosagen
  156. Igenica Biotherapeutics
  157. ImClone Systems
  158. Immune Biosolutions
  159. Immunologix
  160. Immunomic Therapeutics
  161. Immunomedics
  162. Immunome
  163. IMAPAC
  164. Immpact
  165. In-Cell-Art
  166. Innovent Biologics
  167. Institute for Transplantation-Urology-Nephrology, Nantes, France 
  168. Institute of Immunology of the Centre de Recherche Public-Santé
  169. Institut Pasteur
  170. Integral Molecular
  171. Intrexon 
  172. IONTAS
  173. Isogenica
  174. iTeos Therapeutics
  175. Janssen Biotech
  176. Jiangsu Hengrui Medicine
  177. Johnson & Johnson
  178. Johnson & Johnson Pharmaceutical Research & Development
  179. Jounce
  180. Kite Pharma
  181. Kodiak Sciences
  182. Knoll
  183. Kymab
  184. Kyowa Hakko Kirin
  185. LakePharma
  186. LAMPIRE Biological Laboratories
  187. Legend Capital
  188. Leland Stanford Junior University
  189. Leiden University Medical Center
  190. Les Laboratoires Servier
  191. Life Sciences Fund Amsterdam
  192. Ligand Pharmaceuticals
  193. Lille Regional University Hospital Centre
  194. MAB Discovery
  195. MabSpace Biosciences
  196. MabVax Therapeutics
  197. Magenta Therapeutics
  198. Maine Biotechnology Services
  199. Malin Corporation
  200. MassBiologics
  201. Massachusetts General Hospital
  202. Maverick Therapeutics
  203. Medarex
  204. MedImmune
  205. Meditope Biosciences
  206. Memo Therapeutics
  207. Memorial Sloan Kettering Cancer Center
  208. Merck Serono
  209. Mersana Therapeutics
  210. Merus
  211. Millennium Pharmaceuticals
  212. MimAbs
  213. Mitsubishi Tanabe Pharma Corporation
  214. ModiQuest Group
  215. ModiQuest Research
  216. Molcure
  217. Molecular Templates
  218. MorphoSys  
  219. MSM Protein Technologies
  220. Nantes Centre for Research in Transplantation and Immunology
  221. National Cancer Institute
  222. National Institute of Allergy and Infectious Diseases (NIAID)
  223. National Institute on Drug Abuse
  224. NB Health Laboratory
  225. NeoClone
  226. NeoRX Corporation
  227. Neurimmnne
  228. NewSpring Capital
  229. New York University (NYU)
  230. North Coast Biologics
  231. Novartis
  232. Novimmune
  233. Novo Nordisk
  234. Numab
  235. Olympic Protein Technologies
  236. Oncobiologics
  237. Oncothyreon
  238. ONO PHARMACEUTICAL
  239. Open Monoclonal Technology
  240. Organon Teknica
  241. ORI Healthcare Fund
  242. OriMAbs
  243. Ossianix
  244. Oxford Biotherapeutics
  245. OZYME
  246. PacificGMP
  247. Palatin Technologies
  248. Panoply Bio
  249. Pfizer
  250. Ping An Bank
  251. PolyTherics
  252. Potenza Therapeutics
  253. ProtTech
  254. Paris Public Welfare Hospital
  255. Public Investment Bank
  256. PX'Therapeutics
  257. QoolAbs
  258. Quanta BioDesign
  259. Queen Mary University of London
  260. RayBiotech
  261. Regeneron Pharmaceuticals
  262. Research Corporation Technologies
  263. Ribovax Biotechnologies
  264. Roche
  265. SAB Biotherapeutics
  266. Sanofi Aventis
  267. Sea Lane Biotechnologies
  268. Seattle Genetics
  269. Sevion Therapeutics
  270. ShangPharma
  271. Shenogen Pharma
  272. Shenzhen Hepalink Pharmaceutical
  273. Shire
  274. Single Cell Technology
  275. Singapore Immunology Network
  276. Sobi
  277. Soligenix
  278. Specifica
  279. SISCAPA Assay Technologies
  280. Sutro Biopharma
  281. Surface Oncology
  282. Symphogen
  283. Syngene
  284. Synthetic Biologics
  285. Synthon Biopharmaceuticals
  286. Taconic
  287. Takeda Pharmaceutical
  288. Tanabe Research Laboratories
  289. TeneoBio
  290. Tetragenetics
  291. Teva Respiratory
  292. The Chemistry Research Solution (TCRS)
  293. Theraclone Sciences
  294. The Scripps Research Institute
  295. The US Army Edgewood Chemical Biological Center
  296. Tizona Therapeutics
  297. TransGenic
  298. Trellis Bioscience
  299. TRIANNI
  300. Trieza Therapeutics
  301. Tri-Institutional Therapeutics Discovery Institute 
  302. UCB
  303. United Therapeutics
  304. University of Alabama
  305. University of Amsterdam
  306. University of California, Los Angeles 
  307. University of Texas Health Science Center
  308. University Institute of Hematology, Paris
  309. University of Southampton
  310. University of Texas MD Anderson Cancer Center
  311. University of Turku
  312. University of Westminster
  313. Vaccinex
  314. Valeant Pharmaceuticals
  315. Viva Biotech
  316. Viventia Bio
  317. Warburg Pincus
  318. Warwick Effect Polymers
  319. Wellcome Trust
  320. Wellcome Trust Sanger Institute
  321. Woodford Investment Management
  322. Woodford Patient Capital
  323. WuXi AppTec
  324. WuXi Biologics
  325. WuXi PharmaTech
  326. Wyeth
  327. XBiotech
  328. XOMA Corporation
  329. YUMAB

PRICING DETAILS

USD 2,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.